OKUR earnings date and last-quarter result: next report 2026-08-11, last quarter beat, P/E -1.00. Updated 2026-07-23.
OnKure Therapeutics (OKUR) Research Hub
OnKure Therapeutics (OKUR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.48 USD (-1.59%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.00, market cap 0.06B. This hub links to the full technical, earnings and options research available for OKUR.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.48 USD (-1.59%) |
| 52-week range | 2.02 USD – 4.76 USD |
| Trend regime | Range |
| 14-day RSI | 50.8 (Neutral) |
| Trailing P/E | -1.00 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for OKUR
Covered Call on OKUR: how it works, illustrative setup around the real 2.48 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OKUR: how it works, illustrative setup around the real 2.48 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OKUR: how it works, illustrative setup around the real 2.48 USD price, max profit/loss, breakeven and when to use it. Educational.
OKUR technical analysis: range, last 2.48 USD, RSI 50.8, 52w range 2.02 USD–4.76 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is OKUR in?
OnKure Therapeutics (OKUR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OKUR in an uptrend or downtrend?
As of 2026-10-26, OKUR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OKUR's trailing P/E ratio?
OKUR's trailing P/E is -1.00, with a market cap of 0.06B. See the earnings research page for full valuation detail.
When does OKUR next report earnings?
OKUR is next scheduled to report earnings on 2026-08-11.